Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Acer Therapeutics Inc. (ACER)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4200+0.0200 (+0.83%)
At close: 4:00PM EDT
2.4200 0.00 (0.00%)
After hours: 05:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4000
Open2.4100
Bid2.4100 x 800
Ask2.4200 x 1000
Day's Range2.3900 - 2.4500
52 Week Range2.2800 - 5.3900
Volume35,923
Avg. Volume445,327
Market Cap34.631M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-1.6030
Earnings DateAug 11, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • Simply Wall St.

    Acer Therapeutics Inc. (NASDAQ:ACER): Are Analysts Optimistic?

    Acer Therapeutics Inc. ( NASDAQ:ACER ) is possibly approaching a major achievement in its business, so we would like to...

  • Zacks

    Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance

    The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.

  • SmarterAnalyst

    FDA Approves NDA for Acer Therapeutics’ ACER-001; Shares Rise

    Shares of Acer Therapeutics Inc. (ACER) closed 16.5% higher on Wednesday and then declined 5.51%, at the time of writing, in early trade on Thursday. The stock price moved after the pharmaceutical company and its collaboration partner, Relief Therapeutics Holding SA, received the U.S. Food and Drug Administration’s (FDA) green light to file the New Drug Application (NDA) for ACER-001. ACER-001 (sodium phenylbutyrate) is designed for the treatment of patients with various inborn errors of metabol

Advertisement
Advertisement